KH.S. KHAERTYNOV¹, V.A. ANOKHIN¹, S.V. KHALIULLINA¹, E.A. SALAKHOVA¹, O.V. ZHEMKOVA², L.KH. VALIAKHMETOVA², N.A. SHAYKHUTDINOVA², L.YU. MALYKHINA², T.S. UTYUSHEVA²

¹Kazan State Medical University, Kazan

²Republic Clinical Hospital for Infectious Diseases named after Prof. A.F. Agafonov, Kazan

 Contact details:

Khaertynov Kh.S. — Ph. D. (Medicine), Associate Professor of the Department of Children’s Infections

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, tel.: 8-903-342-96-27, e-mail: khalit65@yandex.ru

Vessel endothelial dysfunction is one of the key reasons for the development of thrombosis and unfavorable outcome in patients with COVID-19 coronavirus infection. The risk of thrombosis in patients with COVID-19 may persist during the convalescence period, after discharge from hospital.

The purpose — to assess hemostatis in convalescents with moderate COVID-19.

Material and methods. The study of hemostasis was conducted in 32 patients aged 40 to 79 years with coronavirus infection COVID-19 during the period of convalescence, after discharge from hospital. The control group consisted of 20 healthy people of the same age. The study included determining biomarkers of endothelial dysfunction in venous blood: P-selectin, von Willebrand factor (VWF), D-dimer and thrombomodulin.

Results. It was found that in 24 of 32 patients (75%) after COVID-19 the level of D-dimer was significantly higher than in the control group. Median D-dimer was elevated even 3-4 months after discharge from hospital. P-selectin levels were elevated in 12 (37%) patients who recovered from COVID-19. The median P-selectin was higher than that of the control group 3-4 months after discharge from hospital. A decrease in thrombomodulin levels was recorded in 10 patients (31%). The parameter median was lower than that in the control group only during the first 2 months after discharge from hospital. The values of the FFB factor in patients after COVID-19 did not differ from those in the control group.

Conclusion. A significant proportion of convalescents with moderate COVID-19, even 3-4 months after discharge from hospital, retain endothelial dysfunction and procoagulant potential, which causes the risk of thrombotic complications.

Key words: convalescents of COVID-19, D-dimer, P-selectin, thrombomodulin, von Willebrand factor.

REFERENCES

1. Iba T., Warkentin T.E, Thachil J., Levi M., Levy J.H. Proposal of the Definition for COVID-19-Associated Coagulopathy. J. Clin. Med, 2021, vol. 10 (2), p. 191. DOI: 10.3390/jcm10020191
2. Makatsariya A.D., Slukhanchuk E.V., Bitsadze V.O. et al. COVID-19, hemostasis disorders and the risk of thrombotic complications. Vestnik RAMN, 2020, vol. 57, no. 4, pp. 306–317 (in Russ.).
3. Chen W., Pan J.Y. Anatomical and pathological observation and analysis of SARS and COVID-19: microthrombosis is the main cause of death. Biol. Proc. Online, 2021, vol. 23, pp. 1–12. DOI: 10.1186/s12575-021-00142-y
4. Khismatullin R.R., Ivaeva R.A., Abdullaeva Sh. et al. Pathomorphological manifestations of inflammatory microthrombosis in COVID-19. Kaz. Med. zhurnal, 2022, vol. 103, no. 4, pp. 575–587 (in Russ.).
5. Rungjirajittranon T., Owattanapanich W., Leelakanok N. et al. Thrombotic and hemorrhagic incidences in patients after discharge from COVID-19 infection: a systematic review and metaanalysis. Clin. Appl. Thromb. Hemost, 2021, vol. 27. 10760296211069082. DOI: 10.1177/10760296211069082.
6. Lobastov K.V., Porembskaya O.Ya., Schastlivtsev I.V. Efficacy and safety of antithrombotic therapy for COVID-19. Ambulatornaya khirurgiya, 2021, vol. 18, no. 2, pp. 17–30 (in Russ.). DOI: 10.21518/1995-1477-2021-18-2
7. Fodor A., Tiperciuc B., Login C. et al. Endothelial dysfunction, inflammation, and oxidative stress in COVID-19 — mechanisms and therapeutic targets. Hindawi Oxidative Medicine and Cellular Longevity, 2021. Article ID 8671713.
8. Escher R., Breakey N., Lammle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res, 2020, vol. 190, p. 62. DOI: 10.1016/j.thromres.2020.04.014
9. Agrati C., Sacchi A., Tartaglia E. et al. The role of P-selectin in COVID-19 coagulopathy: an updated review. Int. J. Mol. Sci, 2021, vol. 22 (15), 7942. doi: 10.3390/ijms22157942
10. Yamazaki A., Nukui Y., Kameda T. et al. Variation in presepsin and thrombomodulin levels for predicting COVID-19 mortality. Sci Rep, 2023, vol. 13 (1), 21493. DOI: 10.1038/s41598-023-48633-0
11. Matvienko O.Yu., Golovina O.G., Kobilyanskaya V.A. et al. The state of the hemostasis system in patients who have suffered a new coronavirus infection. Efficiency of anticoagulant prophylaxis. Byulleten’ meditsinskoy nauki, 2022, vol. 3, no. 27, pp. 30–36 (in Russ.).
12. Hulshof A.M., Braeken D.C.W., Ghossein-Doha C. et al. Hemostasis and fibrinolysis in COVID-19 survivors 6 months after intensive care unit discharge. Res. Pract. Thromb. Haemost, 2021, vol. 5 (6), e12579. DOI: 10.1002/rth2.12579
13. Wang Z.F., Su F., Lin X.J. et al. Serum D-dimer changes and prognostic implication in 2009 novel influenza A(H1N1). Thromb. Res, 2011, vol. 127 (3), pp. 198–201. DOI: 10.1016/j.thromres.2010.11.032
14. Klok F.A., Kruip M., van der Meer N.J.M. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res, 2020, vol. 191, pp. 145–147. DOI: 10.1016/j.thromres.2020.04.013
15. Townsend L., Fogarty H., Dyer A. et al. Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J. Thromb. Haemost, 2021, vol. 19 (4), pp. 1064–1070. DOI: 10.1111/jth.15267
16. Li Y., Deng Y., Ye L. et al. Clinical Significance of Plasma D-Dimer in COVID-19 Mortality. Front. Med, 2021, vol. 8, 638097. DOI: 10.3389/fmed.2021.638097
17. Tvaroška I., Selvaraj C., Koca J. Selectins-The Two Dr. Jekyll and Mr. Hyde faces of adhesion molecules-a review. Molecules, 2020, vol. 25 (12), p. 2835. DOI: 10.3390/molecules25122835
18. Watany M.M., Abdou S., Elkolaly R. et al. Evaluation of admission levels of P, E and L selectins as predictors for thrombosis in hospitalized COVID 19 patients. Clin. Exp. Med., 2022, vol. 22 (4), pp. 567–575. DOI: 10.1007/s10238-021-00787-9
19. Goshua G., Pine A.B., Meizlish M.L. et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol, 2020, vol. 7 (8), pp. 575–582. DOI: 10.1016/S2352-3026(20)30216-7
20. Fenyves B.G., Mehta A., Kays K.R. et al. Plasma P-selectin is an early marker of thromboembolism in COVID-19. Am. J. Hematol, 2021, vol. 96 (12), pp. E468–471. DOI: 10.1002/ajh.26372
21. Wang L., Liu G.-J., Chen Y.-X. et al. Combined use of D-dimer and P-selectin for the diagnosis of splenic or portal vein thrombosis following splenectomy. Thrombosis Research, 2010, vol. 125, pp. E206–209. DOI: 10.1016/j.thromres.2009.12.012
22. Tarasev M., Mota S., Gao X. et al. Possible role of P-selectin adhesion in long-COVID: a comparative analysis of a long-COVID case versus an asymptomatic post-COVID case. medRxiv preprint, 2022. DOI: 10.1101/2022.03.09.22271297
23. Song C., Wu G., Chang S. et al. Plasma P-selectin level is associated with severity of coronary heart disease in Chinese Han population. J. Int. Med. Res, 2020, vol. 48 (6), 300060519896437. DOI: 10.1177/0300060519896437
24. Watanabe-Kusunoki K., Nakazawa D., Ishizu A., Atsumi T. Thrombomodulin as a physiological modulator of intravascular injury. Front. Immunol, 2020, vol. 11,575890. DOI: 10.3389/fimmu.2020.575890
25. Francischettia I.M.B., Toomera K., Zhang Y. et al. Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection. E Clinical Medicine, 2021, vol. 39, 101069. DOI: 10.1016/j.eclinm.2021.101069
26. Sayyadi M., Hassani S., Shams M. et al. Status of major hemostatic components in the setting of COVID 19: the efect on endothelium, platelets, coagulation factors, fibrinolytic system, and complement. Annals of Hematology, 2023, vol. 102 (6), pp. 1307–1322. DOI: 10.1007/s00277-023-05234-1
27. Libby P., Lusche T. COVID-19 is, in the end, an endothelial disease. Eur. Heart J, 2020, vol. 41, pp. 3038–3044. DOI: 10.1093/eurheartj/ehaa623
28. Zheng X.L. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annual Review of Medicine, 2015, vol. 66, pp. 211–225. DOI: 10.1146/annurev-med-061813-013241
29. Fujikawa K., Suzuki H., McMullen B. et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood, 2001, vol. 98 (6), pp. 1662–1666. DOI: 10.1182/blood.V98.6.1662
30. Hafez W., Ziade M.A., Arya A. et al. Reduced ADAMTS13 activity in correlation with pathophysiology, severity, and outcome of COVID-19: a retrospective observational study. Int. J. Infect. Dis, 2022, vol. 117, pp. 334–344. DOI: 10.1016/j.ijid.2022.02.019
31. Doevelaar A.A.N., Bachmann M., Hölzer B. et al. Von Willebrand factor multimer formation contributes to immunothrombosis in coronavirus disease 2019. Critical Care Medicine, 2021, vol. 49 (5), pp. E512–520. DOI: 10.1097/CCM.0000000000004918
32. Wibowo A., Pranata R., Lim M.A. et al. Endotheliopathy marked by high von Willebrand factor (vWF) antigen in COVID-19 is associated with poor outcome: a systematic review and meta-analysis. Int. J. Infect. Dis, 2022, vol. 117, pp. 267–273. DOI: 10.1016/j.ijid.2021.06.051